Low expression of GOT2 promotes tumor progress and predicts poor prognosis in hepatocellular carcinoma

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
  MedlineGoogle Scholar
• 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018).
  MedlineGoogle Scholar
• 3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
  MedlineGoogle Scholar
• 4. Park JW, Chen M, Colombo M et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 35(9), 2155–2166 (2015).
  MedlineGoogle Scholar
• 5. Wang CY, Li S. Clinical characteristics and prognosis of 2887 patients with hepatocellular carcinoma: a single center 14 years experience from China. Medicine (Baltimore) 98(4), e14070 (2019). • Hepatocellular carcinoma patients showed 1-, 2-, 3- and 5-year survival rates of 49.3, 35.3, 26.6 and 19.5%, respectively.
  MedlineGoogle Scholar
• 6. Wang XK, Liao XW, Yang CK et al. Oncogene PLCE1 may be a diagnostic biomarker and prognostic biomarker by influencing cell cycle, proliferation, migration, and invasion ability in hepatocellular carcinoma cell lines. J. Cell. Physiol. 235(10), 7003–7017 (2020).
  Medline CASGoogle Scholar
• 7. Jiang Y, Yao B, Chen T et al. BICD1 functions as a prognostic biomarker and promotes hepatocellular carcinoma progression. Pathol. Res. Pract. 216(4), 152858 (2020).
  Medline CASGoogle Scholar
• 8. Chen DH, Wu QW, Li XD, Wang SJ, Zhang ZM. SYPL1 overexpression predicts poor prognosis of hepatocellular carcinoma and associates with epithelial–mesenchymal transition. Oncol. Rep. 38(3), 1533–1542 (2017).
  Medline CASGoogle Scholar
• 9. Liang R, Lin Y, Ye JZ et al. High expression of RBM8A predicts poor patient prognosis and promotes tumor progression in hepatocellular carcinoma. Oncol. Rep. 37(4), 2167–2176 (2017).
  Medline CASGoogle Scholar
• 10. Tang B, Liang X, Tang F et al. Expression of USP22 and survivin is an indicator of malignant behavior in hepatocellular carcinoma. Int. J. Oncol. 47(6), 2208–2216 (2015).
  Medline CASGoogle Scholar
• 11. Fagerberg L, Hallstrom BM, Oksvold P et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol. Cell Proteomics 13(2), 397–406 (2014). • Study that found the liver was the organ with the second highest expression of GOT2.
  Medline CASGoogle Scholar
• 12. Liu M, Liu X, Liu S et al. Big data-based identification of multi-gene prognostic signatures in liver cancer. Front. Oncol. 10, 847 (2020). •• Study that showed low expression of GOT2 is associated with poor prognosis in liver cancer.
  MedlineGoogle Scholar
• 13. Kim KH, Lee MS. Autophagy – a key player in cellular and body metabolism. Nat. Rev. Endocrinol. 10(6), 322–337 (2014).
  Medline CASGoogle Scholar
• 14. Wang H, Liu Y, Wang D et al. The upstream pathway of mTOR-mediated autophagy in liver diseases. Cells 8(12), 1597 (2019).
  Medline CASGoogle Scholar
• 15. Fujimoto A, Furuta M, Totoki Y et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat. Genet. 48(5), 500–509 (2016).
  Medline CASGoogle Scholar
• 16. Kim YC, Guan KL. mTOR: a pharmacologic target for autophagy regulation. J. Clin. Invest. 125(1), 25–32 (2015).
  MedlineGoogle Scholar
• 17. Yang H, Zhou L, Shi Q et al. SIRT3-dependent GOT2 acetylation status affects the malate–aspartate NADH shuttle activity and pancreatic tumor growth. EMBO J. 34(8), 1110–1125 (2015). •• Showed that GOT2 acetylation promotes the net transfer of cytosolic NADH into mitochondria and changes the mitochondrial NADH/NAD(+) redox state to support ATP production. Additionally, GOT2 3K acetylation stimulates NADPH production to suppress reactive oxygen species and protect cells from oxidative damage.
  Medline CASGoogle Scholar
• 18. Yang S, Hwang S, Kim M, Seo SB, Lee JH, Jeong SM. Mitochondrial glutamine metabolism via GOT2 supports pancreatic cancer growth through senescence inhibition. Cell Death Dis. 9(2), 55 (2018).
  MedlineGoogle Scholar
• 19. Feist M, Schwarzfischer P, Heinrich P et al. Cooperative STAT/NF-kappaB signaling regulates lymphoma metabolic reprogramming and aberrant GOT2 expression. Nat. Commun. 9(1), 1514 (2018).
  MedlineGoogle Scholar
• 20. Hong R, Zhang W, Xia X et al. Preventing BRCA1/ZBRK1 repressor complex binding to the GOT2 promoter results in accelerated aspartate biosynthesis and promotion of cell proliferation. Mol. Oncol. 13(4), 959–977 (2019).
  Medline CASGoogle Scholar
• 21. Wang T, Yao W, Li J, He Q, Shao Y, Huang F. Acetyl-CoA from inflammation-induced fatty acids oxidation promotes hepatic malate–aspartate shuttle activity and glycolysis. Am. J. Physiol. Endocrinol. Metab. 315(4), E496–E510 (2018).
  Medline CASGoogle Scholar
• 22. Rogers AB, Fox JG. Inflammation and cancer. I. Rodent models of infectious gastrointestinal and liver cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 286(3), G361–G366 (2004).
  Medline CASGoogle Scholar
• 23. Bishayee A. The role of inflammation and liver cancer. Adv. Exp. Med. Biol. 816, 401–435 (2014).
  Medline CASGoogle Scholar
• 24. Li XF, Chen C, Xiang DM et al. Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance. Hepatology 66(6), 1934–1951 (2017).
  Medline CASGoogle Scholar
• 25. Islam MA, Sooro MA, Zhang P. Autophagic regulation of p62 is critical for cancer therapy. Int. J. Mol. Sci. 19(5), 1405 (2018).
  MedlineGoogle Scholar
• 26. Ichimura Y, Waguri S, Sou YS et al. Phosphorylation of p62 activates the Keap1–Nrf2 pathway during selective autophagy. Mol. Cell 51(5), 618–631 (2013).
  Medline CASGoogle Scholar
• 27. Kabeya Y, Mizushima N, Yamamoto A, Oshitani-Okamoto S, Ohsumi Y, Yoshimori T. LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. J. Cell Sci. 117(Pt 13), 2805–2812 (2004).
  Medline CASGoogle Scholar
• 28. Kabeya Y, Mizushima N, Ueno T et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 19(21), 5720–5728 (2000).
  Medline CASGoogle Scholar
• 29. Ichimura Y, Kominami E, Tanaka K, Komatsu M. Selective turnover of p62/A170/SQSTM1 by autophagy. Autophagy 4(8), 1063–1066 (2008).
  Medline CASGoogle Scholar
• 30. Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat. Rev. Mol. Cell Biol. 21(4), 183–203 (2020).
  Medline CASGoogle Scholar
• 31. Liu L, Das S, Losert W, Parent CA. mTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion. Dev. Cell 19(6), 845–857 (2010).
  Medline CASGoogle Scholar
• 32. Li W, Li Y, Siraj S et al. FUN14 domain-containing 1-mediated mitophagy suppresses hepatocarcinogenesis by inhibition of inflammasome activation in mice. Hepatology 69(2), 604–621 (2019).
  Medline CASGoogle Scholar
• 33. Li TT, Zhu D, Mou T et al. IL-37 induces autophagy in hepatocellular carcinoma cells by inhibiting the PI3K/AKT/mTOR pathway. Mol. Immunol. 87, 132–140 (2017).
  Medline CASGoogle Scholar
• 34. Zhou Y, Wu PW, Yuan XW, Li J, Shi XL. Interleukin-17A inhibits cell autophagy under starvation and promotes cell migration via TAB2/TAB3-p38 mitogen-activated protein kinase pathways in hepatocellular carcinoma. Eur. Rev. Med. Pharmacol. Sci. 20(2), 250–263 (2016).
  Medline CASGoogle Scholar
• 35. Peng WX, Xiong EM, Ge L et al. Egr-1 promotes hypoxia-induced autophagy to enhance chemo-resistance of hepatocellular carcinoma cells. Exp. Cell Res. 340(1), 62–70 (2016). • Investigated the role of Egr-1 in hypoxia-induced autophagy and hypoxia-driven chemoresistance in hepatocellular carcinoma cells.
  Medline CASGoogle Scholar
• 36. Bellot G, Garcia-Medina R, Gounon P et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol. Cell. Biol. 29(10), 2570–2581 (2009).
  Medline CASGoogle Scholar